These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18232649)

  • 41. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-Dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro.
    Řezníčková E; Weitensteiner S; Havlíček L; Jorda R; Gucký T; Berka K; Bazgier V; Zahler S; Kryštof V; Strnad M
    Chem Biol Drug Des; 2015 Dec; 86(6):1528-40. PubMed ID: 26198005
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A convenient synthesis and molecular modeling study of novel purine and pyrimidine derivatives as CDK2/cyclin A3 inhibitors.
    Elgazwy AS; Ismail NS; Elzahabi HS
    Bioorg Med Chem; 2010 Nov; 18(21):7639-50. PubMed ID: 20851615
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Consecutive gold(I)-catalyzed cyclization reactions of o-(buta-1,3-diyn-1-yl-)-substituted N-aryl ureas: a one-pot synthesis of pyrimido[1,6-a]indol-1(2H)-ones and related systems.
    Sharp PP; Banwell MG; Renner J; Lohmann K; Willis AC
    Org Lett; 2013 Jun; 15(11):2616-9. PubMed ID: 23692341
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development and biological evaluation of potent and selective c-KIT(D816V) inhibitors.
    Lee S; Lee H; Kim J; Lee S; Kim SJ; Choi BS; Hong SS; Hong S
    J Med Chem; 2014 Aug; 57(15):6428-43. PubMed ID: 25004409
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of Novel Fluorescent Azaindoles with Cytotoxic Action in A2780 Ovarian Carcinoma Cells.
    Cunha JC; Roma-Rodrigues C; Ferreira JRM; Baptista PV; Fernandes AR; Guieu S; Marques MMB
    ChemMedChem; 2024 Oct; 19(20):e202400225. PubMed ID: 38880774
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
    Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
    Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Synthesis and biological evaluation of 7-azaisoindigo derivatives.
    Wang ZH; Wang T; Yao SN; Chen JC; Hua WY; Yao QZ
    Arch Pharm (Weinheim); 2010 Mar; 343(3):160-6. PubMed ID: 20186868
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Synthesis and antitumor activities of pyrimidines].
    You WW; Zhao PL; Zou M; Zhou ZZ; Duan AN; Wu SG
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 May; 31(5):875-7. PubMed ID: 21602147
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition.
    Fancelli D; Berta D; Bindi S; Cameron A; Cappella P; Carpinelli P; Catana C; Forte B; Giordano P; Giorgini ML; Mantegani S; Marsiglio A; Meroni M; Moll J; Pittalà V; Roletto F; Severino D; Soncini C; Storici P; Tonani R; Varasi M; Vulpetti A; Vianello P
    J Med Chem; 2005 Apr; 48(8):3080-4. PubMed ID: 15828847
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
    Jorda R; Havlíček L; Šturc A; Tušková D; Daumová L; Alam M; Škerlová J; Nekardová M; Peřina M; Pospíšil T; Široká J; Urbánek L; Pachl P; Řezáčová P; Strnad M; Klener P; Kryštof V
    J Med Chem; 2019 May; 62(9):4606-4623. PubMed ID: 30943029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.
    Ahn YM; Vogeti L; Liu CJ; Santhapuram HK; White JM; Vasandani V; Mitscher LA; Lushington GH; Hanson PR; Powell DR; Himes RH; Roby KF; Ye Q; Georg GI
    Bioorg Med Chem; 2007 Jan; 15(2):702-13. PubMed ID: 17123821
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intercalative DNA binding of the marine anticancer drug variolin B.
    Canals A; Arribas-Bosacoma R; Albericio F; Álvarez M; Aymamí J; Coll M
    Sci Rep; 2017 Jan; 7():39680. PubMed ID: 28051169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound.
    Nakano H; Saito N; Parker L; Tada Y; Abe M; Tsuganezawa K; Yokoyama S; Tanaka A; Kojima H; Okabe T; Nagano T
    J Med Chem; 2012 Jun; 55(11):5151-64. PubMed ID: 22540945
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
    Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
    J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
    Mou J; Chen D; Deng Y
    Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
    Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
    Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of cyclin D1-CDK4: synthesis, biological evaluation and structure-activity relationships. Part 2.
    Horiuchi T; Nagata M; Kitagawa M; Akahane K; Uoto K
    Bioorg Med Chem; 2009 Dec; 17(23):7850-60. PubMed ID: 19889545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structure-based design of 2,6,7-trisubstituted-7H-pyrrolo[2,3-d]pyrimidines as Aurora kinases inhibitors.
    Le Brazidec JY; Pasis A; Tam B; Boykin C; Wang D; Marcotte DJ; Claassen G; Chong JH; Chao J; Fan J; Nguyen K; Silvian L; Ling L; Zhang L; Choi M; Teng M; Pathan N; Zhao S; Li T; Taveras A
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4033-7. PubMed ID: 22607669
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of novel CDK inhibitors via scaffold hopping from CAN508.
    Jing L; Tang Y; Xiao Z
    Bioorg Med Chem Lett; 2018 May; 28(8):1386-1391. PubMed ID: 29550093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
    Sutherlin DP; Bao L; Berry M; Castanedo G; Chuckowree I; Dotson J; Folks A; Friedman L; Goldsmith R; Gunzner J; Heffron T; Lesnick J; Lewis C; Mathieu S; Murray J; Nonomiya J; Pang J; Pegg N; Prior WW; Rouge L; Salphati L; Sampath D; Tian Q; Tsui V; Wan NC; Wang S; Wei B; Wiesmann C; Wu P; Zhu BY; Olivero A
    J Med Chem; 2011 Nov; 54(21):7579-87. PubMed ID: 21981714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.